Abstract 286P
Background
Recurrent tumors on MRI described as intermediate T2 signal intensity and ADC quantitative values derived from diffusion sequences are prone to discrepancy. In post surgical setting of oral cavity ADC values are prone to artifacts limiting its utility. This investigation aims to build a decision model using quantitative robust parameters derived from MR imaging.
Methods
Four lesion quantitative parameters ( quantitative T2 lesion signal, T2 lesion/muscle signal ratio, T2 lesion /Tongue signal ratio and ADC values) were assessed in 68 lesions (54 malignant,14 benign). Classification analysis was performed using L1 regularization of features in a Logistic regression, Statistical feature selection methods like ANOVA f-value and chi square and lastly a Entropy based feature selection using decision tree. Results include the probability for malignancy for every descriptor combination in the classification tree. Area under the curve (AUC) used as the statistical parameters to find model efficiency was calculated using software "R".
Results
Logistic regression based classifier could predict the probability of cancer based on T2 based features alone. ADC was not found helpful in predicting the disease. Both scores obtained from ANOVA and Chi-square have a different assumptions about distributions of input feature values and output probabilities, but yielded different scores. Both methods point to T2 as most significant in predicting output probabilities of cancer. Lastly, the decision tree showed T2 based features in addition to ADC provide maximum diagnostic value in determining cancer in patients. The area under the curve of the ROC was .940 for additive T2 and ADC and only 0.74 for ADC values alone. The signal ratios (T2 lesion/muscle signal ratio and T2 lesion /Tongue signal ratio) have an AUC 0.96.
Conclusions
Though each method of feature selection has certain shortfalls due to the assumptions but results demonstrate T2 feature outranking all others, indicating its high predictive power in determining the probability of disease. It is therefore possible to train predictive robust models based on T2 quantitative features with high level of accuracy and precision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
339P - Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation: A phase III study
Presenter: Vikas Talreja
Session: e-Poster Display Session
340P - Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
Presenter: Alfredo Chua
Session: e-Poster Display Session
341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy
Presenter: Andree Kurniawan
Session: e-Poster Display Session
342P - Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer
Presenter: Satoshi Horasawa
Session: e-Poster Display Session
343P - Head-to-head comparison of palonosetron versus granisetron for prevention of chemotherapy induced nausea and vomiting: Systematic review and meta-analysis
Presenter: Chin-Hung Hsu
Session: e-Poster Display Session
344P - Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Presenter: Kohei Fujita
Session: e-Poster Display Session
345P - Thromboembolic events in brain tumour patients on bevacizumab
Presenter: Gunjesh Singh
Session: e-Poster Display Session
346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Presenter: Susanna Hutajulu
Session: e-Poster Display Session
347P - Histamine blockade with loratadine for prevention of granulocyte-colony stimulating factor (G-CSF)-associated bone pain: A meta-analysis
Presenter: Mel Valerie Ordinario
Session: e-Poster Display Session
348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)
Presenter: Michio Nakamura
Session: e-Poster Display Session